The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Recap by typeshit. Full story at 90.5 WESA.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
MedPage Today
A JAMA Network Open analysis of Reddit posts also lists fatigue, insomnia and muscle symptoms. MedPage's roundup adds a CagriSema menopause analysis and Walmart's GLP-1 coverage plan.
Longevity Technology reports BodySpec's new offering targets GLP-1 users worried about muscle, with body scans said to take about 12 minutes.
Loading…